An International Journal for Lung Cancer and other thoracic malignancies
Guide for Authors
Guide for Authors
These guidelines generally follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals"
The complete document appears at http://www.icmje.org
Submission to the journal
Full-length original research
articles, review articles and Editorials on clinical and basic aspects of topics represented by the fields of interest of Lung Cancer
are welcome. Letters to the journal are also encouraged. Short communications and Case Reports are generally not accepted for publication
in Lung Cancer unless they describe major new developments of general interest to the Lung Cancer readership. Manuscripts
describing studies on cell lines will not be considered for publication in Lung Cancer unless the results have general implications and
the data compares at least two types of distinct cell lines. Authors of studies on cell lines must also agree to make freely available
to other researchers any of the cells, clones of cells, or DNA or antibodies, etc, that were used in the research reported and that are
not available from commercial suppliers. Manuscripts should be submitted online at http://ees.elsevier.com/lungcancer and
the instructions on this site should be closely followed. For optimal use of the site, authors need an up-to-date web browser (Internet
Explorer or Netscape Navigator) and Adobe Acrobat Reader (Version 6 or later) which is available free at http://www.adobe.com/products/acrobat/readstep2.html.
Authors unable to submit online should contact the Editorial Office:
Suzanne Peedell
Administrative Editor Lung Cancer
Editorial Office
Elsevier Ltd.
The Boulevard
Langford Lane
Kidlington
Oxford OX5 1GB
U.K.
Tel : +44 (0)1865
843282
Fax : +44 (0)1865 843977
Email : lungcancer@elsevier.com
In a covering letter, please identify the
person responsible for editorial correspondence (address, telephone and fax numbers and e-mail address). The covering letter must be
signed by the corresponding author on behalf of all authors. All authors should have made substantial contributions to all of the following:
(1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article
or revising it critically for important intellectual content, (3) final approval of the version to be submitted. Also include details
of any previous submission. Authors should supply the names and email addresses of up to three potential reviewers for their manuscript.
Please do not suggest reviewers from your own institution, previous or current collaborators, or Editorial Board members. Please do not
contact any reviewers you have suggested.
Acknowledgements All contributors who do not meet the criteria for authorship as
defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided
purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they
had any writing assistance and identify the entity that paid for this assistance.
Randomised controlled trials All randomised
controlled trials submitted for publication in Lung Cancer should include a completed Consolidated Standards of Reporting Trials
(CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information. Lung Cancer also recommends that authors adopt the proposal from the International Committee of Medical Journal Editors (ICMJE)
which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must
register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract
of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention
or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed
for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can
be found at www.icmje.org.
Ethics Work on human beings that is submitted to Lung Cancer should comply
with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical research involving human
subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo,
Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September
1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the
institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving experiments with animals
must state that their care was in accordance with institution guidelines. Patients' and volunteers' names, initials, and hospital numbers
should not be used.
Conflict of interest At the end of the text, under a subheading "Conflict of interest statement" all authors
must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias)
their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony,
patent applications/registrations, and grants or other funding.
Role of the funding source All sources of funding should
be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design,
in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript
for publication. If the study sponsors had no such involvement, the authors should so state.
Language of papers is English.
It is required that all submitted manuscripts be written in clear, concise English. Manuscripts should be typewritten (double
spaced) with 4cm margins, and on one side of the paper only. Letters intended for publication should be a maximum of 500
words, 10 references, and one table or figure, and should be sent to the Editor.
Structure of manuscripts
1. Manuscripts
should be written in English. Authors whose native language is not English are strongly advised to have their manuscripts checked by
an English-speaking colleague prior to submission.
2. Manuscripts should be typewritten, typed on one side of the paper (with numbered
lines), with wide margins and double spacing throughout, i.e. also for abstracts, footnotes and references. Every page of the manuscripts,
including the title page, references, tables, etc. should be numbered. However, in the text no reference should be made to page numbers;
if necessary, one may refer to sections. Underline words that should be in italics, and do not underline any other words. Avoid excessive
usage of italics to emphasize part of the text.
3. Manuscripts in general should be organized in the following order:
Title (should
be clear, descriptive and not too long)
Name(s) of author(s)
Complete postal address(es) of affiliations
Full telephone,
Fax No. and email address of the corresponding author
Present address(es) of author(s) if applicable
Complete correspondence
address and email address to which the proofs should be sent
Summary, all articles should start with a brief, one paragraph summary
Key words (indexing terms), a list of 6-8 key words must be provided with every article
Introduction
Material studied, area descriptions,
methods, techniques
Results
Discussion
Conclusion
Acknowledgements, Conflict of interest statement, and acknowledgement
of the role of the funding source for the study.
References
Tables
4. In typing the manuscript, titles and subtitles should
not be run within the text. They should be typed on a separate line, without indentation. Use lower-case lettertype.
5. Conflict
of interest statement: all authors must disclose any financial or personal relationships with other people or organisations that could
inappropriately influence (bias) their work. All sources of funding should also be declared as an acknowledgement at the end of the text.
Authors should acknowledge whether they had any writing assistance and if so identify the entity that paid for this assistance.
6. SI units should be used.
7. Elsevier reserves the privilege of returning to the author for revision accepted manuscripts and illustrations
which are not in the proper form given in this guide.
Figures
Line drawings (including graphs) should be submitted in
a form suitable for immediate reproduction. For advice on correctly formatting electronic images, visit http://authors.elsevier.com.
For illustrations that cannot be submitted electronically please contact the Editorial Office. Any halftone illustrations (photographs)
must be of top quality with as much contrast as possible to ensure good and accurate reproduction, with any lettering large enough to
permit photographic reproduction. Figures should be numbered in Arabic numerals in order of appearance in the text, where they are referred
to as Fig.1, Fig.2, etc. A scale bar should appear on the figure rather than the magnification given in the legend. Reproduction in colour
will have to be approved by the Editors. The extra costs of colour reproduction will be charged to the author(s). Width of figures should
be approximately twice the height, to yield an optimum printed format. All illustrations must have a legend, which should be typed on
a separate page.
Tables
Should bear a short descriptive title and should also be typed on separate sheets, including
legends. They should be numbered in sequence in Roman numerals.
References
Should be numbered in the order they appear
within the manuscript and listed on a separate sheet; in the text they should be referred to by numbers in brackets. Literature references
must consist of names and authors' initials, title of paper referred to, abbreviated title of periodical, year, the volume and first
and last page numbers of the paper, the abbreviations of journal titles should conform to those adopted by List of Serial Title Word
Abbreviations, CIEPS/ISDS, Paris, 1985 (ISBN 2-904938-02-8).
In the reference list, periodicals [1], single author books [2]
and multi-author books [3] should accord with the following examples:
[1] Chang A, Boros L, Garrow G, Asbury R. Paclitaxel by 3-hour
infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Sem Oncol 1995;22:124-7.
[2] DeVita
VTJ, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: J.B. Lippincott Co., 1993.
[3] Gurman
AS, Kniskern DP. Family therapy outcome research: knowns and unknowns. In: Gurman AS, Kniskern DP, editors. Handbook of family therapy.
New York: Brunner/Maazel, 1981:742-75.
Copyright
Upon acceptance of an article, authors will be asked to sign a "Journal
Publishing Agreement'' (for more information on this and copyright see http://authors.elsevier.com). Acceptance of the agreement
will ensure the widest possible dissemination of information. An e-mail (or letter) will be sent to the corresponding author confirming
receipt of the manuscript together with a 'Journal Publishing Agreement' form. If excerpts from other copyrighted works are included,
the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted
forms for use by authors in these cases: contact Elsevier's Rights Department, Philadelphia, PA, USA. Tel: (+1) 215 238 7869; Fax : (+1)
215 238 2239; Email healthpermissions@elsevier.com. Requests may also be completed online via the Elsevier homepage (http://www.elsevier.com/locate/permissions).
Proofs
One set of page proofs in PDF format will be sent by e-mail to the corresponding author (if we do not have an
e-mail address then paper proofs will be sent by post). Elsevier now sends PDF proofs which can be annotated; for this you will need
to download Adobe Reader version 7 available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions
on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return
to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections
and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail,
or by post.
Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the
Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that
all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of
your article if no response is received.
Offprints
The corresponding author, at no cost, will be provided with a PDF
file of the article via e-mail or, alternatively, 25 free paper offprints. The PDF file is a watermarked version of the published article
and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Additional paper
offprints can be ordered by the authors. An order form with prices will be sent to the corresponding author.
Special Subject Repositories
Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post
certain articles. The following agreements have been established for authors whose articles have been accepted for publication in an
Elsevier journal and whose underlying research is supported by one of the following funding bodies: * National Institutes of Health.
Elsevier will send a version of the author's accepted manuscript that includes author revisions following peer-review for public access
posting 12 months after final publication. Because the NIH 'Public Access' policy is voluntary, authors may elect not to deposit such
articles in PMC. If you wish to 'opt out' and not deposit to PMC, you may indicate this by sending an e-mail to NIHauthorrequest@elsevier.com.
More information regarding the agreement between Elsevier and the National Institutes of Health can be found at http://www.elsevier.com/wps/find/authorshome.authors/nihauthorrequest
* The Wellcome Trust. Elsevier will send to PMC the version of the author's manuscript that reflects all author-agreed changes
including those made post peer review, for public access posting immediately after final publication. Authors are required to initially
subsidize their manuscript with fees reimbursed by the Wellcome Trust. Wellcome Trust authors, whose manuscripts are subsidized, will
have the corresponding articles made free to non-subscribers on ScienceDirect (www.sciencedirect.com/) and Elsevier's electronic
publishing platforms. More information regarding the agreement between Elsevier and The Wellcome Trust can be found at http://www.elsevier.com/wps/find/authorshome.authors/wellcometrustauthors
